Hoffmann-la Roche Inc.

Genentech, Inc.

F. Hoffmann-la Roche Ag

Nathan Robert Scott

Nancy-Ellen Haynes

Jefferson Wright Tilley

Yimin Qian

Kshitij Chhabilbhai Thakkar

Sherrie Lynn Pietranico-Cole

Kevin Richard Guertin

Sung-Sau So

Denis John Kertesz

Ramakanth Sarabu

Robert Francis Kester

Paul Gillespie

Robert Alan Goodnow, Jr

Nader Fotouhi

Steven Joseph Berthel

Lida Qi

Lee Apostle McDermott

Michael Paul Myers

Matthew Michael Hamilton

Alexander Mayweg

Steven Gregory Mischke

Mark Edward Zak

Wendy Lea Corbett

Shaoqing Chen

Johannes Cornelius Hermann

Eric Mertz

Kyungjin Kim

Adrian Wai-Hing Cheung

Agnieszka Kowalczyk

Francis A Mennona

Pamela Loreen Rossman

Qiang Zhang

Lin Yi

Kevin W Anderson

John A Brinkman

Stuart Hayden

Joseph Anthony Bilotta

Bruce Lester Banner

Nancy Ellen Haynes

Alexander V Mayweg

Robert Alan Goodnow Jr

Kevin William DrANDERSON

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as obesity, hyperlipidemia, hypercholesterolemia and diabetes and other related disorders and diseases, and may be useful for other diseases such as NASH, atherosclerosis, cardiovascular diseases, hypothyroidism, thyroid cancer and other disorders and diseases related thereto.

Thyroid hormone analogs

There are provided compounds of the formula (I) wherein Q, Rand Rare defined herein. The compounds have activity as anticancer agents.

Pyrrolopyrimidone and pyrrolopyridone inhibitors of tankyrase

The invention relates to JNK inhibitors and corresponding methods, formulations, and compositions for inhibiting JNK and treating JNK-mediated disorders. The application discloses JNK inhibitors, as described below in Formula I: wherein the variables are as defined herein. The compounds and compositions disclosed herein are useful to modulate the activity of JNK and treat diseases associated with JNK activity. Disclosed are methods and formulations for inhibiting JNK and treating JNK-mediated disorders, and the like, with the compounds, and processes for making said compounds, and corresponding compositions, disclosed herein.

Adamantyl compounds

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.

Pyridazinone glucokinase activators

Provided herein are compounds of the formula (I):  as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as obesity, hyperlipidemia, hypercholesterolemia and diabetes and other related disorders and diseases, and may be useful for other diseases such as NASH, atherosclerosis, cardiovascular diseases, hypothyroidism, thyroid cancer and other disorders and diseases related thereto.

Prodrugs of thyroid hormone analogs

Pyrrolidinone glucokinase activators

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, type II diabetes mellitus and metabolic syndrome.

Adamantyl-pyrazole carboxamides as inhibitors of 11&#x3b2;-hdroxysteroid dehydrogenase

Pyrazolones as inhibitors of 11&#x3b2;-hydroxysteroid dehydrogenase

The present invention provides a compound according to formula I where the substituent designations are provided in the specification. Pharmaceutical compositions comprising a compound according to formula I are also provided.

5-substituted-six-membered heteroaromatic glucokinase activators

Growing community of inventors

Livingston, NJ, United States of America

Nathan Robert Scott